Safety of amphotericin B formutations

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 4 SUPPL. 10, 2009, Pages 5-6

  Sterba, Jaroslav ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX;

ARTICLE; ASPERGILLOSIS; CANCER PATIENT; CD4+ T LYMPHOCYTE; CHEMOPROPHYLAXIS; CYTOKINE RELEASE; DRUG DOSAGE FORM; DRUG RESPONSE; DRUG SAFETY; DRUG USE; HIGH RISK POPULATION; HUMAN; IMMUNOSTIMULATION; INVASIVE CANDIDIASIS; MORTALITY; MYCOSIS; NEPHROTOXICITY; PEDIATRICS; RISK FACTOR; SIDE EFFECT; SYSTEMIC MYCOSIS;

EID: 66749092372     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol. 2004;26:421-426.
2. Filioti I, Iosifidis E, Roilides E. Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients. Expert Opin Pharmacother. 2008;9:3179-3196.
3. Almirante B, Rodriguez D. Antifungal agents in neonates: issues and recommendations. Paediatr Drugs. 2007;9:311-321.
4. Linder N, Klinger G, Shalit I, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother. 2003;52:663-667.
5. Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis. J 1999;18:702-708.
6. Herbrecht R, Auvrignon A, Andres E, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis. 2001;20:77-82.
7. Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2009;88:97-110.
8. Staber P, Langner S, Dornbusch HJ, Neumeister P. Antifungal management in cancer patients. Wien Med Wochenschr. 2007;157:503-510.
9. Pappas PG, Kauffman CA, Andes D, et al; Infectious Diseases Society of America.Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35.
10. Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther. 2003;25: 1295-1320.
11. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother. 2002;49 Suppl 1:7-10.
12. Ghezzi MC, Raponi G, Filadoro F, Mancini C. The release of TNF-alpha and IL-6 from human monocytes stimulated by filtrates of Candida albicans after treatment with amphotericin B. J Antimicrob Chemother. 1994;33:1039-1043.
13. Sau K, Mambula SS, Latz E, Henneke P, Golenbock DT, Levitz SM. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem. 2003;278:37561-37568.
14. Turtinen LW, Prall DN, Bremer LA, Nauss RE, Hartsel SC. Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations. Antimicrob Agents Chemother.2004;48:396-403.
15. Turtinen LW, Bremer LA, Prall DN, Schwartzhoff J, Hartsel SC. Distinct cytokine release profiles from human endothelial and THP-1 macrophage-like cells exposed to different amphotericin B formulations. Immunopharmacol Immunotoxicol. 2005;27:85-93.
16. Simitsopoulou M, Roilides E, Dotis J, et al. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother. 2005;49:1397-1403.
17. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses. 1995;38:459-465.
18. Sterba J. Persistent fever and neutropenia in a child: infusion-related toxicity "fear factor"? Presented at: 5th Amphocil Family Meeting. Verona, Italy. November 15, 2008.
19. McGuire TR, Trickler WJ, Smith L, Hoie EB, Miller DW. Release of TNF-alpha and IL-1beta from porcine brain endothelium corresponds to the pyrogenic potential of three marketed formulations of amphotericin. Inflamm Res. 2005;54:375-379.
20. Pai MP, Norenberg JP, Telepak RA, Sidney DS, Yang S. Assessment of effective renal plasma flow, enzymuria, and cytokine release in healthy volunteers receiving a single dose of amphotericin B desoxycholate. Antimicrob Agents Chemother. 2005;49:3784-3788.